Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 20/20 | 0.98 |
| ▸ | PRKAB2 | O43741 | 16/20 | 0.91 |
| ▸ | PRKAG1 | P54619 | 16/20 | 0.91 |
| ▸ | PRKAA1 | Q13131 | 16/20 | 0.91 |
| ▸ | PRKAG3 | Q9UGI9 | 16/20 | 0.91 |
| ▸ | PRKAG2 | Q9UGJ0 | 16/20 | 0.91 |
| ▸ | PRKAB1 | Q9Y478 | 16/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518208 | 0.99 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL18013666 | 0.96 | PRKAA2 (0.93) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL517680 | 0.95 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL517980 | 0.95 | PRKAA2 (0.90) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL12199998 | 0.95 | PRKAA2 (0.90) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518421 | 0.94 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL16190087 | 0.94 | PRKAA2 (0.91) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518515 | 0.94 | PRKAA2 (0.90) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518212 | 0.94 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518975 | 0.94 | PRKAA2 (0.89) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391616-B1 | CARBOXAMIDE COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | claimed |
| WO-2015048547-A2 | METHODS FOR USING AND BIOMARKERS FOR AMPK-ACTIVATING COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | claimed |
| US-8846600-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | claimed |
| US-20130131078-A1 | Carboxamide Compounds And Methods For Using The Same | MIDCAP FINANCIAL TRUST | 2013-05-23 | — | — | US | claimed |
| US-8362235-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100190802-A1 | CARBOXAMIDE COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS INC. (US) | 2010-07-29 | — | — | US | claimed |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-9663496-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160229838-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | MIDCAP FINANCIAL TRUST | 2016-08-11 | — | — | US | disclosed |
| US-20120028954-A1 | Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011123681-A1 | METHODS FOR USING CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2010088392-A1 | CARBOXAMIDE COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20100190802-A1 | CARBOXAMIDE COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190802-A1 | CARBOXAMIDE COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS INC. (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | PRKAA2 413/4885PRKAB2 541/4885PRKAG1 860/4885 |
| US-20160229838-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | PRKAA2 7/4885PRKAB2 5/4885PRKAG1 1/4885 |
| US-20120028954-A1 | Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same | AK2, PC, PRKAG2 | PRKAA2 6/4885PRKAB2 5/4885PRKAG1 4/4885 |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | PRKAA2 7/4885PRKAB2 5/4885PRKAG1 1/4885 |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | PRKAA2 7/4885PRKAB2 5/4885PRKAG1 1/4885 |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | PRKAA2 7/4885PRKAB2 5/4885PRKAG1 1/4885 |
| US-20100190802-A1 | CARBOXAMIDE COMPOUNDS AND METHODS FOR USING THE SAME | PC, AK2, PRKAA1 | PRKAA2 4/4885PRKAB2 9/4885PRKAG1 6/4885 |
| US-20130131078-A1 | Carboxamide Compounds And Methods For Using The Same | PC, AK2, PRKAA1 | PRKAA2 4/4885PRKAB2 9/4885PRKAG1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.